Live Breaking News & Updates on Molecular Biochemistry|Page 14
Stay updated with breaking news from Molecular biochemistry. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
(2) ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / March 10, 2021. Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the upcoming presentation of four posters with data supporting three of the company s immunotherapy programs at the American Academy for Cancer Research (AACR) Virtual Annual Meeting running April 10-15, 2021. The accepted research describes multiple aspects of validation for the unique mechanisms of these therapies in development for treating a wide range of tumor types. Accepted abstract titles include: MP0317 (targeting CD40 and FAP) MP0317, a FAPxCD40 targeting multi-specific DARPin® therapeutic, drives immune activation and leads to macrophage repolarization in vitro and ex vivo ....
Molecular Partners AG: Molecular Partners and Novartis Report Positive Initial Results from Phase 1 Study of its COVID-19 Antiviral Therapy, Ensovibep, in Healthy Volunteers Predictable exposure seen post administration, confirming the expected half-life of 2-3 weeks Global phase 2/3 registrational study planned to initiate in Q2 2021 ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / March 9, 2021 / Molecular Partners AG (SWX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, and its collaborator Novartis, today announced initial results from its ongoing phase 1 study of its first tri-specific COVID-19 antiviral treatment, ensovibep (MP0420), in healthy volunteers. In the placebo-controlled phase 1 study, healthy volunteers were randomized 3:1 to receive an infusion of ensovibep, or placebo, respectively. Two dosing cohorts have been fully enrolled and received a single infusion of ....
Mar 02 2021 Read 592 Times Labs are increasingly choosing INTEGRA Biosciences’ liquid handling instruments to help them address growing workloads associated with Human papilloma virus (HPV) screening. Several studies have recently suggested that PCR-based screening is more accurate and offers earlier detection of pre-cancerous growths than the conventional Papanicolaou (Pap) test and liquid-based cytology, leading to a gradual shift towards molecular diagnostics approaches. The ASSIST PLUS pipetting robot is ideally suited to this type of diagnostic screening workflow, offering fast and easy, walkaway automation of protocols. The Centre de Pathologie du Maine Normandie (CPMN) in Le Mans was the first lab in France to install an ASSIST PLUS to process HPV samples, and this system has now been adopted by several labs nationally. Nucleic acid extraction and PCR set-up are combined into a single program on the ASSIST PLUS, significantly simplifying the workflow and ensuring ....
(1) Sunquest provides various interoperable products and services that work with each other to improve lab efficiency and results accuracy LONDON, March 2, 2021 /PRNewswire/ Based on its recent analysis of the North American laboratory information management systems (LIMS) market for molecular and genetic diagnostics, Frost & Sullivan recognizes Sunquest Information Systems with the 2021 North America Company of the Year Award. Sunquest s comprehensive portfolio of products and services improves operational efficiency, enhances patient care, and lowers healthcare organizations costs across the spectrum. In particular, its Sunquest Mitogen LIMS drives a superior user experience with its built-in audit trails, patient-centric focus, support for multiple workflows and instruments, and adaptability to client needs. ....
DGAP-News: Molecular Health GmbH: Molecular Health and FALCO biosystems team up to provide genetic analysis services using MH Guide/BRCA and MH Guide/Mendel PMS2, respectively. Therefore, testing BRCA1/2 genes and other heritable cancer-associated genes is becoming increasingly important: both to evaluate the affected patient s individual risk of developing cancer [1],[2], and as a predictive biomarker and companion diagnostic test for certain drugs [3]. Whereas MH Guide/BRCA detects variants in HBOC-associated genes, MH Guide/Mendel can analyze large gene panels as well as whole-exome or whole-genome data, so that many different hereditary diseases can be identified at once. With this collaboration in place, Japanese patients will benefit from state-of-the-art genetic identification of inherited diseases like Hereditary Breast and Ovarian Cancer and many other diseases. This will allow sooner diagnosis and potentially earlier therapeutic intervention , said ....